This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kwak, E. L. Articles by Bell, D. W. Search for Related Content PubMed PubMed Citation Articles by Kwak, E. L. Articles by Bell, D. W.

Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

Authors' Affiliations: ¹ Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts; ² Department of Clinical Pharmacology, Oxford University, Oxford, United Kingdom; Departments of ³ Surgery and ⁴ Pathology, Massachusetts General Hospital and Harvard Medical School; ⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and ⁶ Oncology Centre, Royal Wolverhampton Hospital, Wolverhampton, United Kingdom

Requests for reprints: Daphne W. Bell, MGH Cancer Center, CNY7, 149 13th Street, Charlestown, MA 02129. Phone: 617-724-7805; Fax: 617-724-6919; E-mail: bell{at}helix.mgh.harvard.edu.

Purpose: Specific activating mutations within the epidermal growth factor receptor (EGFR) identify a subset of non–small cell lung cancers with dramatic sensitivity to the specific tyrosine kinase inhibitors (TKI), gefitinib and erlotinib. Despite the abundant expression of EGFR protein in a broad range of epithelial cancers, EGFR mutations have not been reported in a substantial fraction of other cancers. Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers.

Experimental Design: We sequenced exons 18 to 21 of EGFR from 21 cases of Barrett's esophagus, 5 cases of high-grade esophageal dysplasia, 17 cases of esophageal adenocarcinoma, and 55 cases of pancreatic adenocarcinoma. Subsets of esophageal (n = 7) and pancreatic cancer cases (n = 5) were obtained from patients who were subsequently treated with gefitinib or erlotinib-capecitabine, respectively.

Results: Mutations of EGFR were identified in two esophageal cancers (11.7%), three cases of Barrett's esophagus (14.2%), and two pancreatic cancers (3.6%). The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in non–small cell lung cancer. We also identified the TKI drug resistance–associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.

Conclusion: The presence of activating mutations within EGFR in both esophageal and pancreatic adenocarcinomas defines a previously unrecognized subset of gastrointestinal tumors in which EGFR signaling may play an important biological role. EGFR mutations in premalignant lesions of Barrett's esophagus also point to these as an early event in transformation of the esophageal epithelium. The role of genotype-directed TKI therapy should be tested in prospective clinical trials.

This article has been cited by other articles:

				J. Yu, S. Kane, J. Wu, E. Benedettini, D. Li, C. Reeves, G. Innocenti, R. Wetzel, K. Crosby, A. Becker, et al. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer Clin. Cancer Res., May 1, 2009; 15(9): 3023 - 3028. [Abstract] [Full Text] [PDF]

				M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, and D. R. Jones Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 699 - 705. [Abstract] [Full Text] [PDF]

				M. A. Morgan, L. A. Parsels, L. E. Kollar, D. P. Normolle, J. Maybaum, and T. S. Lawrence The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer Clin. Cancer Res., August 15, 2008; 14(16): 5142 - 5149. [Abstract] [Full Text] [PDF]

				C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP PNAS, February 12, 2008; 105(6): 2070 - 2075. [Abstract] [Full Text] [PDF]

				A. Duffy, J. Kortmansky, G. K. Schwartz, M. Capanu, S. Puleio, B. Minsky, L. Saltz, D. P. Kelsen, and E. M. O'Reilly A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Ann. Onc., January 1, 2008; 19(1): 86 - 91. [Abstract] [Full Text] [PDF]

				M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, E. L. Kwak, A. Muzikansky, C. Lawrence, et al. Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer J. Clin. Oncol., October 20, 2007; 25(30): 4787 - 4792. [Abstract] [Full Text] [PDF]

				D. R. Ferry, M. Anderson, K. Beddard, S. Tomlinson, P. Atherfold, J. Obszynska, R. Harrison, and J. Jankowski A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response Clin. Cancer Res., October 1, 2007; 13(19): 5869 - 5875. [Abstract] [Full Text] [PDF]

				S. E. Little, D. A. Bax, M. Rodriguez-Pinilla, R. Natrajan, B. Messahel, K. Pritchard-Jones, G. M. Vujanic, J. S. Reis-Filho, and C. Jones Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney Clin. Cancer Res., August 1, 2007; 13(15): 4360 - 4364. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response Ann. Surg. Oncol., July 1, 2007; 14(7): 2150 - 2158. [Abstract] [Full Text] [PDF]

				G. J. Riely, K. A. Politi, V. A. Miller, and W. Pao Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7232 - 7241. [Abstract] [Full Text] [PDF]